(dur-VAL-yoo-mab)
This page contains brief information about durvalumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Durvalumab is approved to treat adults with:
- Biliary tract cancer, including cholangiocarcinoma and gallbladder cancer, that has spread. It is used with gemcitabine hydrochloride and cisplatin.
- Hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery. It is used with tremelimumab-actl.
- Non-small cell lung cancer (NSCLC). It is used:
- Alone in patients with stage III cancer that cannot be removed by surgery but has not worsened after platinum-based chemotherapy and radiation therapy.
- With tremelimumab-actl and platinum-based chemotherapy in patients with cancer that has spread to other parts of the body and does not have an abnormal EGFR gene or ALK gene.
- Small cell lung cancer. It is used with etoposide phosphate and either carboplatin or cisplatin as the first treatment in patients with extensive-stage cancer.
Durvalumab is also being studied in the treatment of other types of cancer.
More About Durvalumab
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Durvalumab – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects
Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer
Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why
Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors
Clinical Trials Accepting Patients
Find Clinical Trials for Durvalumab – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
